Loading stock data…
$18.19-0.37 (-1.99%)
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
Damora Therapeutics, Inc. in the Healthcare sector is trading at $18.19 with a market capitalization of $1.6B. Wall Street consensus targets $46.89 (9 analysts), implying a +157.8% move over the next 12 months. The stock is currently 53% below its 52-week high of $38.33, remaining 29.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.99M↓ | -$30.81M↑ | -$201.70M↓ | -$3.16M↑ | -$3.42M |
| Net Income | -$31.17M↓ | -$27.78M↑ | -$200.74M↓ | -$3.13M↑ | -$3.44M |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that target...